HepaStem Long-Term Safety Registry - Registry for Patients Who Have Been Administered HepaStem

Status: Enrolling by invitation
Location: See all (5) locations...
Study Type: Observational
SUMMARY

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 75
Healthy Volunteers: No
View:

• All patients having received at least one infusion of HepaStem during a previous interventional clinical study conducted by Promethera.

Locations
Other Locations
Belgium
UCL
Brussel
UZ Leuven
Leuven
France
CHU Lille
Lille
CHU Toulouse
Toulouse
Spain
Hospital de Badajoz
Badajoz
Time Frame
Start Date: April 4, 2018
Estimated Completion Date: July 2028
Participants
Target number of participants: 22
Sponsors
Leads: Promethera Therapeutics

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.